

Haematologica
HAEMATOL/2016/142695
Version 3

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

Olivier Kosmider, Marie Passet, Valeria Santini, Uwe Platzbecker, Valerie Andrieu, Gina Zini, Odile Beyne-Rauzy, Agnès Guerci, Erico Masala, Enrico Balleari, Ekaterina Bulycheva, François Dreyfus, Pierre Fenaux, Michaela Fontenay, and Sophie Park

Disclosures: We would like to thank Roche Pharmaceuticals for a research grant, Véronique de Mas for DNA material, and Silke Gloaguen, Rosa Sapena and Elisa Masiera for the registries. This work was supported by a grant (Programme Hospitalier de Recherche Clinique MDS-04) from the Institut National du Cancer (INCa) and the Direction de la Recherche Clinique de l'Assistance-Publique-Hôpitaux de Paris.

Contributions: OK, MF, FD, PF, SP designed research, analyzed data and wrote the paper. MP, EM, EB prepared the materials. VS, UP wrote the paper and contributed with the clinical data. VA, GZ analyzed data. OBR, AG, EB, contributed with the patient clinical data.